PharMerica Corporation (NYSE: PMC), a national provider of institutional pharmacy, specialty infusion and hospital pharmacy management services, today announced that Christopher Schaefer has been appointed Senior Vice President of Corporate Development, a newly created position, effective immediately. He will report to Greg S. Weishar, Chief Executive Officer of PharMerica Corporation.
Mr. Schaefer joins PharMerica from CIT Healthcare, where he served as Director of Healthcare Investment Banking, Leveraged Finance and Mergers & Acquisitions. Prior to that, he worked in business and corporate development at Boston Heart Diagnostics. Mr. Schaeffer brings over fifteen years of experience in investment banking, and will be responsible for PharMerica’s corporate growth strategy, with a particular focus on identifying external growth opportunities.
Mr. Weishar said, "On behalf of the Board and management team, I am pleased to welcome Chris to PharMerica. He brings extensive finance and M&A experience to this new role, and I intend to work closely with him to accelerate our growth and take our company’s performance to the next level. I look forward to drawing on his expertise to advance our growth strategy and continue creating value for shareholders.”
Mr. Schaefer said, “As a strong company with an excellent reputation for its customer-centric technologies and superior pharmacy services, PharMerica is well-positioned to pursue value enhancing opportunities for its shareholders. I look forward to joining the company at this exciting time in its growth and contributing to its success.”
About Christopher Schaefer
Mr. Schaefer, 37, was previously Director of Healthcare Investment Banking, Leveraged Finance and Mergers & Acquisitions at CIT Healthcare. Prior to that, he worked at Boston Heart Diagnostics in business and corporate development. Before joining Boston Health Diagnostics, Mr. Schaefer worked in investment banking at Thomas Weisel Partners, UBS Investment Bank, Robertson Stephens and Deutsche Bank. He received a B.S. in Economics from Harvard University and an M.B.A from New York University, Stern School of Business.